Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app tame your allergies?

NCT ID NCT06603935

Disease control Sponsor: QHSLab, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether digital tools can help people with allergic rhinitis (hay fever) better control their symptoms. About 240 adults will use a smartphone platform that tracks symptoms, sends reminders, and gives personalized advice. Researchers will compare their progress to those receiving standard care over 12 months, looking at symptom severity, medication use, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QHSLab digital platform (Allergy Management Evaluation and Allergic Rhinitis Intervention Steps)
What this could lead to
If successful, this could provide an effective digital tool to help people better control their allergic rhinitis symptoms and improve daily life.
What could go wrong
This is a relatively small, early-stage study testing a digital tool, not a drug. The tool may not significantly improve outcomes over standard care, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years. * Clinically diagnosed with allergic rhinitis and/or sinusitis for at least 6 months. * SNOT-22 score of ≥20, indicating uncontrolled allergic rhinitis. * If Currently receiving treatment for allergic rhinitis and willing to continue treatment during the study. * Able and willing to provide informed consent electronically and comply with the study procedures. Exclusion Criteria: * Individuals under 18 or over 65 years of age. * Pregnant or breastfeeding women. * Recent surgical treatment for nasal polyps (within the last 3 months). * Patients with cystic fibrosis, purulent nasal infections, or any other disease likely to interfere with the study parameters. * Individuals with severe or unstable concurrent diseases or psychological disorders that may compromise participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic sinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis Sinusitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • QHSLab

    West Palm Beach, Florida, 33407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.